Plasma brain natriuretic peptide levels indicating thromboembolism in very elderly patients with non-valvular atrial fibrillation

Circulation Journal

Volumn 71, Issue 9, 2007, Pages 1446-1451

  Watanabe, Daisuke ^a   Shizuka, Kazuhiko ^a   Koyama, Shunichi ^a   Iwamoto, Toshihiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Atrial fibrillation; Brain natriuretic peptide; Thromboembolism; Transesophageal echocardiography; Very elderly patients

Indexed keywords

ACETYLSALICYLIC ACID; BRAIN NATRIURETIC PEPTIDE; WARFARIN;

AGED; ARTICLE; BRAIN EMBOLISM; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FUNCTION; HEART HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; INTRACRANIAL EMBOLISM; MALE; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 34548493921     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1446     Document Type: Article

References (46)

1. Phillips SJ, Whisnant JP, O'Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minesota. Mayo Clin Proc 1990; 65: 344-359.
2. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM, for the CHS Collaborative Research Group. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-241.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke 1991; 22: 983-988.
4. Bogousslavsky J, Adnet-Bonte C, Regli F, Van Melle G, Kappenberger L. Lone atrial fibrillation and stroke. Acta Neurol Scand 1990; 82: 143-146.
5. Petersen P. Thromboembolic complications in atrial fibrillation. Stroke 1990; 21: 4-13.
6. Black IW, Hopkins AP, Lee LCL, Walsh WF. Left atrial spontaneous echo contrast: A clinical and echocardiographic analysis. J Am Coll Cardiol 1991; 18: 398-404.
7. Mugge A, Daniel WG, Hausmann D, Godkle J, Wagenbreth I, Lichtlten PR. Diagnosis of left atrial appendage thrombi by transesophageal echocardiography: Clinical implications and follow-up. Am J Card Imaging 1990; 4: 173-179.
8. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 1994; 23: 961-969.
9. Chan SK, Kannam JP, Douglas PS, Manning WJ. Multiplane transesophageal echocardiographic assessment of left atrial appendage anatomy and function. Am J Cardiol 1995; 76: 528-530.
10. Orsinelli DA, Pearson AC. Usefulness of multiplane transesophageal echocardiography in differentiating left atrial appendage thrombus from pectinate muscles. Am Heart J 1996; 131: 622-623.
11. Veinot JP, Harrity PJ, Gentile F, Khandheria BK, Bailey KR, Eickholt JT, et al. Anatomy of the normal left atrial appendage: A quantitative study of age-related changes in 500 autopsy hearts: Implications for echocardiographic examination. Circulation 1997; 96: 3112-3115.
12. Agmon Y, Khandheria BK, Gentile F, Seward JB. Echocardiographic assessment of the left atrial appendage. J Am Coll Cardiol 1994; 34: 1867-1877.
13. Pollick C, Taylor D. Assessment of left atrial appendage function by transesophageal echocardiography: Implications for the development of thrombus. Circulation 1991; 84: 223-231.
14. Ito T, Suwa M, Hirota Y, Otake Y, Moriguchi A, Kawamura K. Influence of left atrial function on Doppler transmitral and pulmonary venous flow patterns in dilated and hypertrophic cardiomyopathy: Evaluation of left atrial appendage function by transesophageal echocardiography. Am Heart J 1996; 131: 122-130.
15. Mugge A, Kuhn H, Nikutta P, Grote J, Lopez JAG, Daniel WG. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: Identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol 1994; 23: 599-607.
16. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. reduced flow velocity in the left atrial appendage (the Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999; 12: 1080-1087.
17. Shinohara H, Fukuda N, Soeki T, Takeichi N, Yui Y, Tamura Y, et al. Relationship between flow dynamics in the left atrium and hemostatic abnormalities in patients with nonvalvular atrial fibrillation. Jpn Heart J 1998; 39: 721-730.
18. Pongratz G, Brandt-Pohlmann M, Henneke KH, Pohle C, Zink D, Gehlng G, et al. Platelet activation in embolic and preembolic status of patients with nonrheumatic atrial fibrillation. Chest 1997; 111: 929-933.
19. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGergor OGA, et al. Natriuretic peptide system in human heart failure. Circulation 1993; 88: 1004-1009.
20. Ishibashi Y, Shimada T, Sakane T, Takahashi N, Sugamori T, Ohhata S, et al. Contribution of endogenous nitric oxide to basal vasomotor tone of peripheral vessels and plasma B-type natriuretic peptide levels in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1605-1611.
21. Yasue H, Yoshimura M, Sumida H, Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-205.
22. Nishigaki K, Tomita M, Kagawa K, Noda T, Minatoguchi S, Oda H, et al. Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1996; 28: 1234-1242.
23. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Failure 2000; 6: 92-96.
24. Ohta Y, Shimada T, Yoshitomi H, Inoue S, Murakami Y, Shimizu H, et al. Drop on plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Can J Cardiol 2001; 17: 415-420.
25. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natiruretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-1412.
26. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
27. Shimizu H, Murakami Y, Inoue S, Ohta Y, Nakamura K, Katoh H, et al. High plasma brain natriuretic polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fibrillation. Stroke 2002; 33: 1005-1010.
28. Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, Morehead A. Plasma B-type natriuretic peptide levels in systolic heart failure. J Am Coll Cardiol 2004; 43: 416-422.
29. Mak GS, DeMaria A, Clopton P, Maisel AS. Utility of B-natriuretic peptide in the evaluation of ventricular diastolic function. Am Heart J 2004; 148: 895-902.
30. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.
31. Dokainish H, Zoghbi WA, Lakkis NM, Al-Bakshy F, Dhir M, Quinones M, et al. Optimal noninvasive assessment of left ventricular filling pressure: A comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation 2004; 109: 2432-2439.
32. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma BNP as a biochemical marker of high LVEDP in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-832.
33. Nakamura M, Kawata Y, Yoshida H, Arakawa N, Koeda T, Ichikawa T, et al. Relationship between plasma atrial and brain natriuretic peptide concentration and hemodynamic parameters during percutaneous transvenous mitral valvulotomy in patients with mitral stenosis. Am Heart J 1992; 124: 1283-1288.
34. Tharaux PL, Dussaule JC, Hubert-Brieere J, Vahanian A, Acar J, Ardaillou R. Plasma atrial and brain natriuretic peptides in mitral stenosis treated by valvulotomy. Cln Sci (Colch) 1994; 87: 671-677.
35. Furstaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184.
36. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localozation and mechanism of secretion of Btype natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
37. Trovato GM, Carpinteri G. Effects of atrial fibrillation on the increase of atrial natriuretic peptide in congestive heart failure. Recent Prog Med 1994; 85: 570-575.
38. Seino Y, Shimai S, Ibuki C, Itoh K, Takano T, Hayakawa H. Disturbed secretion of atrial natriuretic peptide in patients with persistent atrial standstill: Endocrinologic study. J Am Coll Cardiol 1991; 18: 459-463.
39. Van Den Berg MP, Crijns HJGM, Van Veldhuisen DJ, Van Gelder IC, DeKam PJ, Lie KI. Atrial natriuretic peptide in patients with heart failure and chronic atrial fibrillation. Am Heart J 1998; 135: 242-244.
40. Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K, Akioka K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992; 92: 29-34.
41. Hasegawa K, Fujiwara H, Doyama K. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993; 88: 372-380.
42. Lip GYH, Lip PL, Zarifis J, Watson RDS, Bareford D, Lowe GDO, et al. Fiblin, D-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation: Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94: 425-431.
43. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: A study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997; 29: 106-112.
44. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: Amulticenter, prospective, randomized trial. Stroke 2000; 31: 817-821.
45. Nakagawa K, Hirai T, Sakurai K, Ohara K, Nozawa T, Inoue H. Thoracic aortic plaque enhances hypercoagulability in patients with nonrheumatic atrial fibrillation. Circ J 2007; 71: 52-56.
46. Saito T, Tamura K, Uchida D, Saito T, Togashi M, Nitta T, et al. Histopathological features of the resected left atrial appendage as predictors of recurrence after surgery for atrial fibrillation in valvular heart disease. Circ J 2007; 71: 70-78.